MART-1 TCR gene-modified peripheral blood T cells for the treatment of metastatic melanoma: a phase I/IIa clinical trial [0.03%]
针对转移性黑色素瘤的外周血T细胞经 MART-1 TCR基因修饰治疗I/Iia期临床试验
M W Rohaan,R Gomez-Eerland,J H van den Berg et al.
M W Rohaan et al.
Background: Adoptive cell therapy with peripheral blood T cells expressing transgenic T-cell receptors (TCRs) is an innovative therapeutic approach for solid malignancies. We investigated the safety and feasibility of ado...
Microbiome-based interventions: therapeutic strategies in cancer immunotherapy [0.03%]
基于微生物组的干预措施：癌症免疫治疗中的治疗策略
C Soto Chervin,T F Gajewski
C Soto Chervin
The composition of the commensal microbiota has recently emerged as a key element influencing the efficacy of cancer treatments. It has become apparent that the interplay between the microbiome and immune system within the host influences t...
Function and evolution of the prototypic CD28ζ and 4-1BBζ chimeric antigen receptors [0.03%]
原型CD28ζ和4－1BBζ嵌合抗原受体的功能与进化研究
J Feucht,M Sadelain
J Feucht
T cells engineered to express chimeric antigen receptors (CARs) specific for CD19 have yielded remarkable clinical outcomes in patients with refractory B-cell malignancies. The first CARs to be approved by the US Food and Drug Administratio...
Immune checkpoints in thymic epithelial tumors: challenges and opportunities [0.03%]
胸腺上皮肿瘤中的免疫检查点：挑战和机遇
Nicolas Girard
Nicolas Girard
Thymic malignancies are rare mediastinal cancers, classified according to the World Health Organization's histopathologic classification which distinguishes thymomas from thymic carcinomas. One key consideration when discussing immunotherap...
John B Haanen
John B Haanen
Adoptive cell therapy with tumour-infiltrating lymphocytes: the emerging importance of clonal neoantigen targets for next-generation products in non-small cell lung cancer [0.03%]
肿瘤浸润淋巴细胞的过继性细胞疗法：非小细胞肺癌中下一代产品中克隆新抗原靶点的重要性日益增加
Jane Robertson,Max Salm,Markus Dangl
Jane Robertson
Immune checkpoint blockade has significantly improved clinical outcomes for patients with non-small cell lung cancer (NSCLC) and other solid tumours, but many patients do not respond and acquired resistance is common. Aspects of the tumour ...
Intratumoural immunotherapy: activation of nucleic acid sensing pattern recognition receptors [0.03%]
瘤内免疫治疗：激活核酸感应型模式识别受体
Sudhir Agrawal,Ekambar R Kandimalla
Sudhir Agrawal
Recently, it has become clear that the tumour microenvironment (TME) is important in cancer immunotherapy. While immune checkpoint inhibitors are effective for some patients, the heterogeneous nature and status of the TME ('cold' tumours) p...
Intervention strategies for microbial therapeutics in cancer immunotherapy [0.03%]
癌症免疫治疗中微生物疗法的干预策略
V Gopalakrishnan,B Weiner,C B Ford et al.
V Gopalakrishnan et al.
Immunotherapies have drastically improved clinical outcomes in a wide range of malignancies. Nevertheless, patient responses remain highly variable, and reliable biomarkers that predict responses accurately are not yet fully understood. Com...
Development and applications of computer image analysis algorithms for scoring of PD-L1 immunohistochemistry [0.03%]
计算机图像分析算法在PD-L1免疫组化评分中的应用及研究
L J Inge,E Dennis
L J Inge
Immune checkpoint inhibitors targeting programmed cell death 1 (PD-1) and programmed cell death ligand 1 (PD-L1) have rapidly become integral to standard-of-care therapy for non-small cell lung cancer and other cancers. Immunohistochemical ...
Polycomb repressive complex 2 mutations predict survival benefit in advanced cancer patients treated with immune checkpoint inhibitors [0.03%]
多梳抑制复合物2突变可预测免疫检查点抑制剂治疗晚期癌症患者的生存获益
P J Vlachostergios
P J Vlachostergios
Background: Numerous biomarkers are being tested to enhance the ability of clinicians to predict responses and prognosis after treatment with immune checkpoint inhibitors (ICIs). Polycomb repressive complex 2 (PRC2) is a ...